Temsirolimus

CHEMBL1201182 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1030.3 g/mol

LogP

5.6

Phase

4

This targeted cancer therapy is given intravenously to treat advanced renal cell carcinoma (kidney cancer). It works by blocking a protein called mTOR, which signals cancer cells to grow and multiply. It is also being investigated for use in other cancers.

Molecular Weight

1030.3000 g/mol

LogP

5.60

TPSA

242.00 Å²

Lipinski RO5

Fail

Therapeutic Areas

Age-Related Macular Degeneration Alzheimer's Disease Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Colorectal Cancer Epilepsy Gastroesophageal Reflux Disease Gout Heart Failure Hepatitis C HIV/AIDS Hypertension Infectious Disease Inflammatory Bowel Disease Leukemia Lymphoma Major Depressive Disorder Melanoma Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Osteoporosis Ovarian Cancer Pancreatic Cancer Parkinson's Disease Prostate Cancer Respiratory Disease Rheumatoid Arthritis Stroke Systemic Lupus Erythematosus Thyroid Cancer Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C

InChI

InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1

Molecular Formula

C56H87NO16

HBD / HBA

4 / 16

Rotatable Bonds

11

Heavy Atoms

73

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This targeted cancer therapy is given intravenously to treat advanced renal cell carcinoma (kidney cancer). It works by blocking a protein called mTOR, which signals cancer cells to grow and multiply. It is also being investigated for use in other cancers.

Yes, Temsirolimus is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201182. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918289. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Temsirolimus on PillFYI

Structure

Quick Data

Formula: C56H87NO16
Synonyms: 1

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.